Asia-Pacific Probiotics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The asia-Pacific probiotics market size is expected to grow from USD 35.56 billion in 2025 to USD 37.28 billion in 2026 and is forecast to reach USD 63.69 billion by 2031 at 9.85% CAGR over 2026-2031. This report is Segmented by Product Type (Probiotic Foods, Probiotic Drinks, Dietary Supplements, and Animal Feed and Nutrition), Distribution Channels (Supermarket/Hypermarkets, Pharmacies and Drug Stores, Convenience/Grocery Stores, Online Stores, and Others), and Geography. Market Forecasts are Provided in Terms of Value (USD).

Asia-Pacific Probiotics Market Trends and Insights

Increasing Demand for Functional Foods and Beverages

In 2025, functional food and beverage categories dominated the consumption of probiotic ingredients. However, a notable shift towards strain-specific formulations is altering the dynamics for suppliers. In July 2024, Morinaga Milk Industry received regulatory approval in China for its Bifidobacterium longum subsp. infantis M63. This move is strategically aimed at infant formula producers keen on mimicking the oligosaccharide metabolizing prowess of breastfed infants' gut microbiota. Also in July 2024, Nestlé kicked off the STARLIT clinical trial in China. The trial focuses on an infant formula enriched with human milk oligosaccharides (specifically 2' fucosyllactose and lacto N neotetraose) and probiotics. This formulation is crafted to meet the premarket efficacy data stipulation set by China's National Health Commission for novel food ingredients. In October 2025, Yakult unveiled Y1000 in Singapore. This fermented milk drink boasts Lacticaseibacillus paracasei strain Shirota, delivering 10 billion CFU per 100 mL. Marketed for its benefits on stress reduction and sleep quality, this marks a departure from Yakult's traditional focus on digestive health, aligning with the heightened emphasis on mental wellness in the post-pandemic landscape. Kirin Holdings, in 2025, revealed plans for its plasma lactic acid bacteria, Lactococcus lactis strain Plasma. Set to debut in Taiwan in 2025, the brand eyes expansions into Australia and Southeast Asia by 2027, bolstered by immune modulation claims backed by over 30 peer-reviewed studies.

Rising Incidence of Digestive Disorders Fuels Market Expansion

By 2024, the prevalence of irritable bowel syndrome (IBS) stood at 16.7% in Japan, 13% in China, and 12.9% in South Korea. However, less than 30% of these patients were administered probiotics as a primary treatment. This notable treatment gap has caught the attention of pharmaceutical and nutraceutical companies, prompting them to initiate physician education programs. In 2024, Changi General Hospital in Singapore kicked off a clinical trial focusing on multi-strain probiotics for post-infectious IBS. This condition, prevalent in 10 to 15% of travelers returning from Southeast Asia, an area known for endemic enteric pathogen exposure, has become a focal point for the hospital. Meanwhile, the DIVINE trial in Indonesia, backed by DSM Firmenich, investigated the effects of Bifidobacterium lactis HN019 on constipation-predominant IBS. After 4 weeks, results showcased a 40% uptick in bowel movement frequency compared to the placebo group. Such compelling evidence is influencing insurers in Japan and South Korea to consider reimbursing probiotic supplements for patients diagnosed with IBS. This policy shift, driven by the Ministry of Health, Labour and Welfare, Japan, has the potential to generate an additional USD 200 to 300 million in annual demand by 2028.

Elevated Research and Development Costs

Established multinationals, with their deeper pockets, find it easier to navigate the capital-intensive landscape of strain characterization, stability testing, and clinical trials. Bringing a novel probiotic strain from the lab to regulatory approval demands an investment of USD 5 to 10 million and a commitment of 3 to 5 years. This lengthy and costly process often deters investments in niche areas like oral health or dermatology. In Japan, the Ministry of Health, Labor and Welfare has set a high bar for food submissions, requiring human clinical trials with participant numbers exceeding 50. This poses a challenge for smaller formulators, who often rely on contract research organizations for support. Meanwhile, in 2024, China's National Health Commission mandated whole genome sequencing for novel probiotic strains. This step, aimed at screening out antibiotic resistance genes and virulence factors, adds an extra USD 50,000 to 100,000 to pre-market costs. Down under in Australia, the Therapeutic Goods Administration made waves in 2024 by reclassifying high-dose probiotics as complementary medicines. This shift brought about stringent Good Manufacturing Practice audits and pharmacovigilance reporting, leading to a 20 to 30% hike in compliance overheads.

Other drivers and restraints analyzed in the detailed report include:

• Growing Preference for Natural, Organic, and Non-GMO Probiotics
• Proliferation of Retail and E-Commerce Distribution Channels
• Intense Competition from Alternative Wellness Products

Segment Analysis

Dietary supplements are projected to grow at a CAGR of 10.62% through 2031, driven by urban professionals favoring convenience and targeted benefits over traditional dairy formats. In 2025, probiotic foods commanded a 55.71% market share, bolstered by yogurt's widespread popularity in Japan and South Korea, where annual per capita consumption surpassed 15 kg. However, growth is slowing as consumers pivot to capsules, which offer higher CFU counts without the drawbacks of added sugars or refrigeration. In 2025, probiotic drinks, divided into dairy and non-dairy categories, garnered substantial market value. Non-dairy variants, including coconut, almond, and oat-based options, are witnessing a surge in Australia and urban India. This growth is largely attributed to the high prevalence of lactose intolerance (60 to 70 percent in East Asia) and the rising trend of vegan diets. While animal feed and nutrition represent a smaller segment, they are rapidly gaining traction in aquaculture-heavy nations like Vietnam, Thailand, and Indonesia. Here, strains like Bacillus subtilis and Lactobacillus are supplanting traditional antibiotic growth promoters in shrimp and tilapia farming, leading to an 8 to 12 percent boost in feed conversion ratios and a decrease in pathogen loads, as noted by FAO Fisheries and Aquaculture.

Yogurt continues to dominate the probiotic food landscape, but it is grappling with margin pressures from private label rivals and a growing consumer disinterest in single-strain offerings. The 2024 to 2025 period saw infant formulas and baby foods carve out a lucrative niche. Notably, Morinaga's Bifidobacterium longum subsp. Infantis M63 received the green light in China, allowing manufacturers to charge a 20 to 30 percent premium over standard offerings. While bakery items, breakfast cereals, snacks, and confections accounted for under 5 percent of probiotic ingredient usage in 2025, limited by thermal processes that deactivate live cultures, innovations are on the horizon. Heat-stable postbiotic formats are beginning to change the game. In 2024, Japan's Foods with Function Claims registry approved heat-killed Lactobacillus strains for baked goods, signaling a potential boom in this segment. Regulatory clarity in South Korea and Japan is proving advantageous for dietary supplements. Their health functional food frameworks allow claims like "helps maintain healthy cholesterol levels," a privilege not extended to conventional foods. This regulatory edge not only bolsters compliance but also paves the way for premium pricing.

Complete Report Scope:

• By Product Type
  • Probiotic Foods
    • Yogurt
    • Bakery and Breakfast Cereals
    • Infant Formula and Baby Foods
    • Snacks and Confectionery
    • Others
  • Probiotic Drinks
    • Dairy-based
    • Non-dairy
  • Dietary Supplements
  • Animal Feed and Nutrition
• By Distribution Channels
  • Supermarket/Hypermarkets
  • Pharmacies and Drug Stores
  • Convinience/Grocery Stores
  • Online Stores
  • Others
• By Geography
  • China
  • India
  • Japan
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • South Korea
  • Rest of Asia -Pacific

List of Companies Covered in this Report:

• Danone SA
• Nestlé SA
• Yakult Honsha Co. Ltd
• BioGaia AB
• PepsiCo Inc.
• DSM-Firmenich
• Morinaga Milk Industry Co., Ltd.
• Probi AB
• Chr. Hansen Holding A/S
• Shanghai Dongsheng Health Industry Co., Ltd.
• Zhejiang Hisun Pharmaceuticals Co., Ltd.
• Sanzyme Biologics Pvt. Ltd.
• H&H Group
• Jiangzhong Pharmaceutical
• Probiotech International
• Winclove Probiotics
• By-Health Co., Ltd.
• SYNBIO Technologies
• Nutraceutix
• Shanghai SINE Pharmaceutical Laboratories Co., Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support